Literature DB >> 21901503

Red cell exchange transfusion as a rescue therapy for tacrolimus toxicity in a paediatric renal transplant.

Hugh McCarthy1, Carol Inward, Steve Marriage, Peter Astley, E Jane Tizard.   

Abstract

Tacrolimus is a widely used macrolide immunosuppressant that has a narrow therapeutic index and potential side effects including neurotoxicity. A 20-month-old boy with kidney disease secondary to prune belly syndrome variant, managed on peritoneal dialysis, received a deceased donor transplant. Standard immunosuppression was used. There was good early graft function. Post-transplant he developed fungal peritonitis associated with a significant reduction in graft function and was treated with caspofungin and fluconazole. Despite tacrolimus dose reduction he developed a rapid rise in tacrolimus concentration to a maximum of 72 ng/ml with an otherwise unexplained reduction in consciousness. He underwent a single volume exchange transfusion with packed red cells and 4.5% albumin (ratio 2:1). This resulted in immediate reduction of his tacrolimus concentration from 61.8 ng/ml to 35.2 ng/ml. The neurological deficit rapidly resolved. The fungal peritonitis was eradicated. Renal function recovered from a nadir of eGFR <10 ml/min/1.73 m² to a baseline of 30 ml/min/1.73 m². At 30 months post-transplant the child has creatinine of 1.4 mg/dl (eGFR of 31 ml/min/1.73 m²), and is developmentally appropriate with no neurological deficit. Red cell exchange transfusion is a potentially safe and effective way of managing severe and symptomatic tacrolimus toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901503     DOI: 10.1007/s00467-011-1985-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Use of phenobarbital in the management of acute tacrolimus toxicity: a case report.

Authors:  G E McLaughlin; M Rossique-Gonzalez; B Gelman; T Kato
Journal:  Transplant Proc       Date:  2000-05       Impact factor: 1.066

2.  Tacrolimus-induced neurotoxicity in kidney transplant recipients.

Authors:  P Veroux; M Veroux; C Puliatti; W Morale; D Cappello; M Valvo; M Macarone
Journal:  Transplant Proc       Date:  2002-12       Impact factor: 1.066

Review 3.  Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.

Authors:  Qisi Wu; Christian Marescaux; Valérie Wolff; Mi-Young Jeung; Romain Kessler; Valérie Lauer; Yangmei Chen
Journal:  Eur Neurol       Date:  2010-08-12       Impact factor: 1.710

4.  Blood tacrolimus concentration unchanged by plasmapheresis.

Authors:  D Przepiorka; J Suzuki; C Ippoliti; J P Hester; H A Fritsche
Journal:  Am J Hosp Pharm       Date:  1994-07-01

5.  Pharmacogenetics of calcineurin inhibitors in renal transplantation.

Authors:  Eliecer Coto; Beatriz Tavira
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

6.  Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient.

Authors:  Rubén E Quirós-Tejeira; I-Fen Chang; Lisa J Bristow; Saul J Karpen; John A Goss
Journal:  Pediatr Transplant       Date:  2005-12

7.  Tacrolimus intoxication resolved by gastrointestinal bleeding: case report.

Authors:  F C Renner; A Staak; L Bur Am Orde; H-D Walmrath; R Weimer
Journal:  Transplant Proc       Date:  2007-03       Impact factor: 1.066

Review 8.  FK 506: an update.

Authors:  G B Klintmalm
Journal:  Clin Transplant       Date:  1994-04       Impact factor: 2.863

9.  Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.

Authors:  Marie Antignac; Benoit Barrou; Robert Farinotti; Philippe Lechat; Saïk Urien
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

Review 10.  Tacrolimus: a further update of its use in the management of organ transplantation.

Authors:  Lesley J Scott; Kate McKeage; Susan J Keam; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.